Free Trial

Immatics (IMTXW) Stock Price, News & Analysis

+0.50 (+25.00%)
(As of 05/24/2024 08:50 PM ET)
Today's Range
50-Day Range
52-Week Range
148,500 shs
Average Volume
7,768 shs
Market Capitalization
P/E Ratio
Dividend Yield
Price Target
IMTXW stock logo

About Immatics Stock (NASDAQ:IMTXW)

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

IMTXW Stock Price History

IMTXW Stock News Headlines

See More Headlines
Receive IMTXW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Current Symbol
Year Founded


Pretax Margin


Sales & Book Value

Annual Sales
$74.47 million


Free Float
Not Optionable
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Harpreet Singh Ph.D. (Age 49)
    CEO, MD, Member of Management Board & Executive Director
    Comp: $883.18k
  • Dr. Toni Weinschenk Ph.D. (Age 50)
    Co-Founder & Chief Innovation Officer
  • Mr. Arnd Christ MBA (Age 58)
    Chief Financial Officer
  • Mr. Steffen Walter Ph.D. (Age 47)
    Chief Operations Officer
  • Mr. Edward A. Sturchio J.D. (Age 48)
    General Counsel & Secretary
  • Dr. Carsten Reinhardt M.D. (Age 57)
    Ph.D., Chief Development Officer
  • Mr. Cedrik M. Britten M.D. (Age 48)
    Chief Medical Officer
  • Mr. Jordan Silverstein (Age 44)
    Head of Strategy
  • Dr. Hans-Georg Rammensee Ph.D.
    Co-Founder & Member of the Scientific Advisory Board
  • Mr. Ephraim Hofsäß M.Sc.
    Vice President of SEC Reporting & Accounting

IMTXW Stock Analysis - Frequently Asked Questions

How have IMTXW shares performed in 2024?

Immatics' stock was trading at $2.92 at the start of the year. Since then, IMTXW stock has decreased by 14.4% and is now trading at $2.50.
View the best growth stocks for 2024 here

How do I buy shares of Immatics?

Shares of IMTXW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMTXW) was last updated on 5/27/2024 by Staff

From Our Partners